journal
MENU ▼
Read by QxMD icon Read
search

Diabetes & Metabolism

journal
https://www.readbyqxmd.com/read/28527866/informal-caregiving-as-a-risk-factor-for-type-2-diabetes-in-individuals-with-favourable-and-unfavourable-psychosocial-work-environments-a-longitudinal-multi-cohort-study
#1
J Mortensen, A J Clark, T Lange, G S Andersen, M Goldberg, C H Ramlau-Hansen, J Head, M Kivimäki, I E H Madsen, C Leineweber, R Lund, R Rugulies, M Zins, H Westerlund, N H Rod
AIM: To examine whether informal caregiving is associated with increased risk of type 2 diabetes (T2D), and whether job strain and social support at work modify the association. METHODS: Individual participant's data were pooled from three cohort studies-the French GAZEL study, the Swedish Longitudinal Occupational Survey of Health (SLOSH) and the British Whitehall II study-a total of 21,243 study subjects. Informal caregiving was defined as unpaid care for a closely related person...
May 17, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28526322/low-serum-creatinine-is-a-type-2-diabetes-risk-factor-in-men-and-women-the-yuport-health-checkup-center-cohort-study
#2
S Kashima, K Inoue, M Matsumoto, K Akimoto
AIM: Type 2 diabetes (T2D) is a risk factor for muscle loss and subsequent frailty. The reverse association, however, may also happen. This study examined whether serum creatinine level, an indicator of muscle mass, predicted diabetes development. In addition, a role for body mass index (BMI) as an effect modifier of creatinine levels was evaluated. METHODS: This cohort study included 9667 subjects without diabetes or hypertension and with normal creatinine levels at baseline...
May 16, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28522196/impact-of-glucose-lowering-therapies-on-risk-of-stroke-in-type-2-diabetes
#3
REVIEW
F Bonnet, A J Scheen
Patients with type 2 diabetes (T2D) have an increased risk of stroke compared with people without diabetes. However, the effects of glucose-lowering drugs on risk of ischaemic stroke in T2D have been less extensively investigated than in coronary heart disease. Some evidence, including the UKPDS, has suggested a reduced risk of stroke with metformin, although the number of studies is limited. Inhibition of the KATP channels increases ischaemic brain lesions in animals. This is in agreement with a recent meta-analysis showing an increased risk of stroke with sulphonylureas vs...
May 15, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28499696/fenofibrate-decreases-plasma-ceramide-in-type-2-diabetes-patients-a-novel-marker-of-cvd
#4
M Croyal, Z Kaabia, L León, S Ramin-Mangata, T Baty, F Fall, S Billon-Crossouard, A Aguesse, T Hollstein, D R Sullivan, E Nobecourt, G Lambert, M Krempf
AIM: The benefit of the lipid-lowering drug fenofibrate on cardiovascular outcomes is controversial. Our aim was to find new circulating markers to identify those patients most likely to benefit from fenofibrate prescription. METHODS: Analyses were conducted of plasma samples collected from 102 patients with type 2 diabetes, enrolled in the FIELD trial, before and after fenofibrate treatment (200mg/day). Non-targeted and targeted lipid analyses and apolipoprotein measurements were made using mass spectrometry methods...
May 9, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28499695/dapagliflozin-modulates-glucagon-secretion-in-an-sglt2-independent-manner-in-murine-alpha-cells
#5
A Solini, G Sebastiani, L Nigi, E Santini, C Rossi, F Dotta
AIM: SGLT2 inhibitors reduce renal glucose uptake through an insulin-independent mechanism. They also increase glucagon concentration, although the extent to which this is due to a direct effect on pancreatic alpha cells remains unclear. METHODS: In the present work, αTC1 cells treated with the SGLT2 inhibitor dapagliflozin (Dapa) were analyzed for glucose transporters, molecular mediators of hormone secretion, glucagon and GLP-1 release, and the effects of somatostatin...
May 9, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28495365/the-yin-and-yang-of-apolipoprotein-ciii
#6
LETTER
K Åvall, P-O Berggren, L Juntti-Berggren
No abstract text is available yet for this article.
May 8, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28483292/acute-pancreatitis-with-dipeptidyl-peptidase-4-dpp4-inhibitor-or-fulminant-type-1-diabetes
#7
LETTER
C Amouyal, P Levy, F Andreelli, A Hartemann
No abstract text is available yet for this article.
May 5, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28483291/psychosocial-determinants-of-non-adherence-to-antidiabetic-drug-treatment-a-prospective-cohort-study
#8
LETTER
L Guénette, A Zongo, L Guillaumie, S Lauzier, L Blais, J-P Grégoire, J Moisan
No abstract text is available yet for this article.
May 5, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28476578/canagliflozin-as-a-replacement-therapy-for-patients-with-type-2-diabetes-not-responding-to-glp-1-receptor-agonists
#9
LETTER
M D Garcia de Lucas, J O Sierra
No abstract text is available yet for this article.
May 2, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28455114/association-of-fasting-serum-insulin-and-cancer-mortality-in-a-healthy-population-28-year-follow-up-of-the-french-telecom-study
#10
M Wargny, B Balkau, C Lange, M-A Charles, P Giral, D Simon
AIMS: Epidemiologic, pharmacoepidemiologic and pathophysiologic evidence points consistently to an association between type 2 diabetes and cancer. This association could be explained by hyperinsulinemia induced by insulin resistance. We studied the association between fasting serum insulin (FSI) and cancer mortality in a population of non-diabetic individuals. METHODS: We followed 3117 healthy workers (50.2% women), included in the TELECOM cohort study, between 1985 and 1987; their median age was 38 years (Q1-Q3=30-50)...
April 25, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28455113/a-synopsis-of-brown-adipose-tissue-imaging-modalities-for-clinical-research
#11
REVIEW
L Sun, J Yan, L Sun, S S Velan, M K S Leow
Body weight gain results from a chronic excess of energy intake over energy expenditure. Accentuating endogenous energy expenditure has been accorded considerable attention ever since the presence of brown adipose tissue (BAT) in adult humans was recognized, given that BAT is known to increase energy expenditure via thermogenesis. Besides classic BAT, significant strides in our understanding of inducible brown adipocytes have been made regarding its development and function. While it is ideal to study BAT histologically, its relatively inaccessible anatomical locations and the inherent risks associated with biopsy preclude invasive techniques to evaluate BAT on a routine basis...
April 25, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28438547/metformin-is-associated-with-a-lower-risk-of-colorectal-cancer-in-taiwanese-patients-with-type-2-diabetes-a-retrospective-cohort-analysis
#12
C-H Tseng
BACKGROUND: The association between metformin and colorectal cancer (CRC) has rarely been investigated in Asian populations. METHODS: This retrospective cohort study included patients with newly diagnosed type 2 diabetes during 1999-2005, recruited from Taiwan's National Health Insurance database. A total of 169,601 patients (original cohort: 153,270 ever-users and 16,331 never-users of metformin) and a subgroup of 1:1 propensity-score-matched pairs of 16,331 ever-users and 16,331 never-users (matched cohort) were followed up to 31 December 2011...
April 21, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28433560/glycaemic-control-and-hypoglycaemia-with-insulin-glargine-300-u-ml-compared-with-glargine-100-u-ml-in-japanese-adults-with-type-2-diabetes-using-basal-insulin-plus-oral-anti-hyperglycaemic-drugs-edition-jp-2-randomised-12-month-trial-including-6-month-extension
#13
Y Terauchi, M Koyama, X Cheng, M Sumi, M C Riddle, G B Bolli, T Hirose
AIMS: To compare insulin glargine 300 U/mL (Gla-300) with glargine 100 U/mL (Gla-100) in Japanese adults with uncontrolled type 2 diabetes on basal insulin and oral anti-hyperglycaemic drugs over 12 months. METHODS: EDITION JP 2 was a randomised, open-label, phase 3 study. Following a 6-month treatment period, participants continued receiving previously assigned once daily Gla-300 or Gla-100, plus oral anti-hyperglycaemic drugs, in a 6-month extension period. Glycaemic control, hypoglycaemia and adverse events were assessed...
April 19, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28392167/associations-between-a-fetal-imprinted-gene-allele-score-and-late-pregnancy-maternal-glucose-concentrations
#14
C J Petry, K Mooslehner, P Prentice, M G Hayes, M Nodzenski, D M Scholtens, I A Hughes, C L Acerini, K K Ong, W L Lowe, D B Dunger
AIM: We hypothesised that some of the genetic risk for gestational diabetes (GDM) is due to the fetal genome affecting maternal glucose concentrations. Previously, we found associations between fetal IGF2 gene variants and maternal glucose concentrations in late pregnancy. METHODS: In the present study, we tested associations between SNP alleles from 15 fetal imprinted genes and maternal glucose concentrations in late pregnancy in the Cambridge Baby Growth and Wellbeing cohorts (1160 DNA trios)...
April 6, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28389064/importance-of-alternative-site-blood-glucose-testing-in-the-diagnosis-of-artifactual-hypoglycaemia-in-systemic-scleroderma
#15
LETTER
V Dubourdieu, H Mosbah, C Amouyal, A Hartemann, F Andreelli
No abstract text is available yet for this article.
April 4, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28365211/a-parental-history-of-diabetes-is-associated-with-a-high-risk-of-retinopathy-in-patients-with-type-2-diabetes
#16
LETTER
G Lapeyre, A Cougnard-Grégoire, M-N Delyfer, C Delcourt, S Hadjadj, L Blanco, E Pupier, M-B Rougier, K Rajaobelina, K Mohammedi, M Hugo, J F Korobelnik, V Rigalleau
No abstract text is available yet for this article.
March 29, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28347654/efficacy-and-safety-of-alirocumab-in-insulin-treated-patients-with-type-1-or-type-2-diabetes-and-high-cardiovascular-risk-rationale-and-design-of-the-odyssey-dm-insulin-trial
#17
B Cariou, L A Leiter, D Müller-Wieland, G Bigot, H M Colhoun, S Del Prato, R R Henry, F J Tinahones, A Letierce, L Aurand, J Maroni, K K Ray, M Bujas-Bobanovic
AIMS: The coadministration of alirocumab, a PCSK9 inhibitor for treatment of hypercholesterolaemia, and insulin in diabetes mellitus (DM) requires further study. Described here is the rationale behind a phase-IIIb study designed to characterize the efficacy and safety of alirocumab in insulin-treated patients with type 1 (T1) or type 2 (T2) DM with hypercholesterolaemia and high cardiovascular (CV) risk. METHODS: ODYSSEY DM-INSULIN (NCT02585778) is a randomized, double-blind, placebo-controlled, multicentre study that planned to enrol around 400 T2 and up to 100 T1 insulin-treated DM patients...
March 24, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28325589/all-cause-mortality-in-patients-with-diabetes-under-glucagon-like-peptide-1-agonists-a-population-based-open-cohort-study
#18
K A Toulis, W Hanif, P Saravanan, B H Willis, T Marshall, B Kumarendran, K Gokhale, S Ghosh, K K Cheng, P Narendran, G N Thomas, K Nirantharakumar
AIM: The glucagon-like peptide-1 receptor agonist (GLP1a) liraglutide has been described to benefit patients with type 2 diabetes mellitus (T2DM) at high cardiovascular risk. However, there are still uncertainties relating to these cardiovascular benefits: whether they also apply to an unselected diabetic population that includes low-risk patients, represent a class-effect, and could be observed in a real-world setting. METHODS: We conducted a population-based, retrospective open cohort study using data derived from The Health Improvement Network database between Jan 2008 to Sept 2015...
March 18, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28318913/characteristics-and-predictors-of-obstructive-sleep-apnoea-in-patients-with-type-2-diabetes
#19
LETTER
M José M C Souza, A Kelley L Medeiros, M M B Carvalho, C A Medeiros, T C Lustosa, T Leiane Guerra de Couto, R R M Silva, M A B B Correia, R A P Oliveira, M V F P Silva, I V Secundo, R P Pedrosa
No abstract text is available yet for this article.
March 16, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28318912/less-liver-fibrosis-in-metabolically-healthy-compared-with-metabolically-unhealthy-obese-patients-with-non-alcoholic-fatty-liver-disease
#20
Y Gutiérrez-Grobe, E Juárez-Hernández, B A Sánchez-Jiménez, M H Uribe-Ramos, M H Ramos-Ostos, M Uribe, N C Chávez-Tapia
AIM: This cross-sectional study evaluated liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD), and compared the characteristics of metabolically healthy obese (MHO) with metabolically unhealthy obese (MUHO) patients. METHODS: The study was nested within a randomized clinical trial (RCT) and included obese patients with NAFLD, as determined by liver ultrasonography. Fibrosis was assessed by transient elastography, and AST-to-platelet ratio index (APRI) and NAFLD score...
March 16, 2017: Diabetes & Metabolism
journal
journal
32535
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"